These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 32161598)

  • 1. Low-Dose Gemcitabine Treatment Enhances Immunogenicity and Natural Killer Cell-Driven Tumor Immunity in Lung Cancer.
    Zhang X; Wang D; Li Z; Jiao D; Jin L; Cong J; Zheng X; Xu L
    Front Immunol; 2020; 11():331. PubMed ID: 32161598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells.
    Okita R; Wolf D; Yasuda K; Maeda A; Yukawa T; Saisho S; Shimizu K; Yamaguchi Y; Oka M; Nakayama E; Lundqvist A; Kiessling R; Seliger B; Nakata M
    PLoS One; 2015; 10(10):e0139809. PubMed ID: 26439264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced antitumor activity of gemcitabine by polysaccharide-induced NK cell activation and immune cytotoxicity reduction in vitro/vivo.
    Xie X; Zhou Y; Wang X; Guo J; Li J; Fan H; Dou J; Shen B; Zhou C
    Carbohydr Polym; 2017 Oct; 173():360-371. PubMed ID: 28732877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination doxorubicin and interferon-α therapy stimulates immunogenicity of murine pancreatic cancer Panc02 cells via up-regulation of NKG2D ligands and MHC class I.
    Wang WJ; Qin SH; Zhang JW; Jiang YY; Zhang JN; Zhao L
    Asian Pac J Cancer Prev; 2014; 15(22):9667-72. PubMed ID: 25520086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.
    Suzuki E; Kapoor V; Jassar AS; Kaiser LR; Albelda SM
    Clin Cancer Res; 2005 Sep; 11(18):6713-21. PubMed ID: 16166452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NKG2D-directed cytokine-activated killer lymphocyte therapy combined with gemcitabine for patients with chemoresistant metastatic solid tumors.
    Morisaki T; Hirano T; Koya N; Kiyota A; Tanaka H; Umebayashi M; Onishi H; Katano M
    Anticancer Res; 2014 Aug; 34(8):4529-38. PubMed ID: 25075096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of platinum‑based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death‑1 ligand 1 and HLA class I in non‑small cell lung cancer.
    Okita R; Maeda A; Shimizu K; Nojima Y; Saisho S; Nakata M
    Oncol Rep; 2019 Aug; 42(2):839-848. PubMed ID: 31173242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-Fluorouracil and interleukin-2 immunochemotherapy enhances immunogenicity of non-small cell lung cancer A549 cells through upregulation of NKG2D ligands.
    Zhao L; Wang WJ; Zhang JN; Zhang XY
    Asian Pac J Cancer Prev; 2014; 15(9):4039-44. PubMed ID: 24935593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation.
    He S; Yin T; Li D; Gao X; Wan Y; Ma X; Ye T; Guo F; Sun J; Lin Z; Wang Y
    J Transl Med; 2013 Aug; 11():186. PubMed ID: 23937717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas.
    Davis M; Conlon K; Bohac GC; Barcenas J; Leslie W; Watkins L; Lamzabi I; Deng Y; Li Y; Plate JM
    J Immunother; 2012 Oct; 35(8):629-40. PubMed ID: 22996369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methionine enkephalin (MENK) suppresses lung cancer by regulating the Bcl-2/Bax/caspase-3 signaling pathway and enhancing natural killer cell-driven tumor immunity.
    Zhang S; Liu N; Ma M; Huang H; Handley M; Bai X; Shan F
    Int Immunopharmacol; 2021 Sep; 98():107837. PubMed ID: 34116288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy.
    Bellone G; Novarino A; Vizio B; Brondino G; Addeo A; Prati A; Giacobino A; Campra D; Fronda GR; Ciuffreda L
    Int J Oncol; 2009 Jun; 34(6):1701-15. PubMed ID: 19424589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer.
    Glorieux C; Xia X; You X; Wang Z; Han Y; Yang J; Noppe G; Meester C; Ling J; Robert A; Zhang H; Li SP; Wang H; Chiao PJ; Zhang L; Li X; Huang P
    J Adv Res; 2022 Sep; 40():109-124. PubMed ID: 36100320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engagement of TLR3, TLR7, and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12.
    Girart MV; Fuertes MB; Domaica CI; Rossi LE; Zwirner NW
    J Immunol; 2007 Sep; 179(6):3472-9. PubMed ID: 17804388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polysaccharide enhanced NK cell cytotoxicity against pancreatic cancer via TLR4/MAPKs/NF-κB pathway in vitro/vivo.
    Xie X; Ma L; Zhou Y; Shen W; Xu D; Dou J; Shen B; Zhou C
    Carbohydr Polym; 2019 Dec; 225():115223. PubMed ID: 31521276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-Fluorouracil and interferon-α immunochemotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligands and MHC class I.
    Khallouf H; Märten A; Serba S; Teichgräber V; Büchler MW; Jäger D; Schmidt J
    J Immunother; 2012 Apr; 35(3):245-53. PubMed ID: 22421942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.
    Shi L; Lin H; Li G; Sun Y; Shen J; Xu J; Lin C; Yeh S; Cai X; Chang C
    Cancer Lett; 2016 Apr; 373(1):45-56. PubMed ID: 26805759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MULT1E/mIL-12: a novel bifunctional protein for natural killer cell activation.
    Tietje A; Li J; Yu X; Wei Y
    Gene Ther; 2014 May; 21(5):468-75. PubMed ID: 24572784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
    Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
    Front Immunol; 2020; 11():40. PubMed ID: 32082316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells.
    Solari JIG; Filippi-Chiela E; Pilar ES; Nunes V; Gonzalez EA; Figueiró F; Andrade CF; Klamt F
    BMC Cancer; 2020 May; 20(1):474. PubMed ID: 32456685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.